Table 1 Characteristics of study population stratified by palivizumab prophylaxis through end of first RSV season
Characteristic | Fully prophylaxed infants (N= 2828) | Partially prophylaxed infants (N= 5615) | p-value (fully versus partially prophylaxed) | ||
|---|---|---|---|---|---|
Number | Percent | Number | Percent | ||
Demographics | |||||
Sex | |||||
Male | 1468 | 51.9% | 2989 | 53.2% | 0.250 |
Female | 1360 | 48.1% | 2626 | 46.8% | |
Race | |||||
White | 1283 | 45.4% | 2029 | 36.1% | <0.001 |
Black | 795 | 28.1% | 1759 | 31.3% | |
Hispanic | 235 | 8.3% | 724 | 12.9% | |
Other/unknown | 515 | 18.2% | 1103 | 19.6% | |
Population density | |||||
Urban | 1898 | 67.1% | 4230 | 75.3% | <0.001 |
Rural | 924 | 32.7% | 1370 | 24.4% | |
Unknown | 6 | 0.2% | 15 | 0.3% | |
With capitated insurance | 545 | 19.3% | 1724 | 30.7% | <0.001 |
With basis of eligibility blind/disabled | 301 | 10.6% | 520 | 9.3% | 0.043 |
Comorbidities of Interest | |||||
Any CLDP | 192 | 6.8% | 609 | 10.8% | <0.001 |
Any CHD | 378 | 13.4% | 864 | 15.3% | 0.013 |
Other comorbidity | 1565 | 55.6% | 3171 | 56.3% | 0.322 |
Birth-related metrics | |||||
Birth month | |||||
May | 629 | 22.2% | 1267 | 22.6% | <0.001 |
June | 737 | 26.1% | 1256 | 22.4% | |
July | 724 | 25.6% | 1311 | 23.3% | |
August | 523 | 18.5% | 1210 | 21.5% | |
September | 215 | 7.6% | 571 | 10.2% | |
Birth type | |||||
Singleton | 2092 | 74.0% | 4199 | 74.8% | <0.001 |
Multiplets | 575 | 20.3% | 982 | 17.5% | |
Unknown | 161 | 5.7% | 434 | 7.7% | |
Gestational age (weeks) | |||||
<33 | 455 | 16.1% | 978 | 17.4% | 0.125 |
33-34 | 1171 | 41.4% | 2011 | 35.8% | <0.001 |
Other* | 73 | 2.6% | 156 | 2.7% | 0.599 |
Live birth/premature, gestational age unknown | 1074 | 38.0% | 2309 | 41.1% | 0.005 |
Birth weight (grams) | |||||
<500 | 14 | 0.5% | 25 | 0.4% | <0.001 |
500-999 | 368 | 13.0% | 820 | 14.6% | |
1000-1499 | 836 | 29.6% | 1496 | 26.6% | |
1500-1999 | 760 | 26.9% | 1329 | 23.7% | |
2000-2499 | 257 | 9.1% | 487 | 8.7% | |
2500+ | 75 | 2.7% | 154 | 2.7% | |
Low birth weight, not otherwise specified | 205 | 7.2% | 471 | 8.4% | |
Missing | 313 | 11.1% | 833 | 14.8% | |
Birth hospitalization | |||||
NICU admission | 2627 | 92.9% | 5103 | 90.9% | 0.002 |
Mean/SD length of stay (days) | 28.9 | 24.9 | 27.0 | 24.7 | 0.001 |
Utilization prior to first palivizumab dose | |||||
Any ED visit or inpatient admission † | 1031 | 36.5% | 2590 | 46.1% | <0.001 |
Any RSV-related hospitalization † | 83 | 2.9% | 334 | 5.9% | <0.001 |
Palivizumab dosing | |||||
Age at first dose (days) | 109.4 | 40.7 | 133.5 | 56.2 | <0.001 |
Number of doses | |||||
Mean/SD | 6.3 | 1.2 | 3.8 | 1.8 | <0.001 |
Median | 6 | 4 | |||
Range | 3-13 | 1-11 | |||